FDA grants approval of modifying treatment for patients with Alzheimer’s Disease
The Food and Drug Administration (FDA) granted traditional approval of a disease-modifying treatment that could potentially give some patients with Alzheimer’s disease something they haven’t had before: a medication that may slow the decline of memory and thinking. Dr. Ronald Petersen, a neurologist and director of the Mayo Clinic Alzheimer’s Disease Research Center stated to KAUS News that lecanemab, a monoclonal antibody, shows promise in removing amyloid plaques, one of the defining features of Alzheimer’s Disease, from the brain…
As with any drug, Dr. Petersen says lecanemab has potential side effects which can be serious….
Dr. Petersen says the data from the lecanemab study was an important step forward in the fight against a disease which robs patients of their most human qualities….
Dr. Peterson went on to talk about who would be good candidate for treatment…
